An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
about
Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenzaH5N1 vaccines in humansEmergence and pandemic potential of swine-origin H1N1 influenza virusA cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults.Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patientsClinical vaccine development for H5N1 influenza.Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetPreclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccinesAn update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.African green monkeys recapitulate the clinical experience with replication of live attenuated pandemic influenza virus vaccine candidates.Continuing challenges in influenza.Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge.Current status and progress of prepandemic and pandemic influenza vaccine development.Emulsion-based adjuvants for influenza vaccines.Improving seasonal and pandemic influenza vaccinesEvaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults.Pandemic influenza vaccines: meeting the supply, distribution and deployment challengesEconomic analysis of pandemic influenza vaccination strategies in Singapore.Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemicPreservation of the immunogenicity of dry-powder influenza H5N1 whole inactivated virus vaccine at elevated storage temperatures.Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks.Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individualsPoly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccineEffect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.MF59 adjuvant: the best insurance against influenza strain diversity.Pandemic influenza vaccines - the challenges.New technologies for influenza vaccines.Permissible variation in the 3' non-coding region of the haemagglutinin genome segment of the H5N1 candidate influenza vaccine virus NIBRG-14 [corrected].The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants.Long-term vaccine-induced heterologous protection against H5N1 influenza viruses in the ferret model.Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of ageUnusual patterns of IgG avidity in some young children following two doses of the adjuvanted pandemic H1N1 (2009) influenza virus vaccine.Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated by antibodies to virus haemagglutinin.Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.Safety and immunogenicity of a plant-produced recombinant hemagglutinin-based influenza vaccine (HAI-05) derived from A/Indonesia/05/2005 (H5N1) influenza virus: a phase 1 randomized, double-blind, placebo-controlled, dose-escalation study in healthH5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses.Why do adaptive immune responses cross-react?Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 studyElectroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus.
P2860
Q21091074-AD4C31FC-DB81-475E-BCEA-1737DE11AF41Q27000896-43CEC83A-6DE6-4B78-B73B-89B2757DC46CQ29619003-AF1D3758-9A45-42ED-BE38-749DF3335C91Q30210342-61EB274B-233A-4ECE-81B4-05FB4EF4D53AQ30210481-18931A40-B12D-4443-A52B-7A9D435F15AFQ30222083-CE4D92A7-DBBA-4FB2-BA61-8EF7D0C92963Q30227194-62818E92-D227-47E1-B5C6-00173D9A0E68Q30352121-0D0E9D52-90E8-43E1-B33E-F04FF7DA51B3Q30352329-8507D7DB-611B-42A2-82CE-7376CEB549C9Q30362332-6863F426-2F82-4DF1-BBC1-562A93E59894Q30363190-F9E0E108-5F11-4812-9B00-2EF9519FA23DQ30375784-BCF8D85C-4469-4EF0-A674-AFCD52166790Q30375975-E6BC5C98-7F38-41C4-918C-78E1E21C7EFAQ30375985-D5C13E7B-CB25-47C8-A99B-8465BC35E5B3Q30377211-BA2EEE0B-B5F8-443F-A487-17B8630F02EEQ30378263-B293EF34-37FE-45DE-BEE2-5C6F011DBA92Q30379211-405D409F-3C3A-42B0-AF11-EF3149118768Q30380974-DBD7ABA6-F99C-4181-82F6-BC35C42184B3Q30383451-9E7BDAAB-FBB3-43D3-ABF3-5BB9E98EB3CFQ30386212-3C18FDD3-96FB-446B-89DF-4A707BAA7C7CQ30389582-2DD80E1F-AEE3-4346-BC96-B3EABD297CF4Q30394896-81CA38D2-AF42-41EE-9727-69A4D73EC81FQ30397400-A2ABE2A2-046E-40BB-8B1C-5B405C44AFE5Q30400146-5BD06F2A-ADE3-407F-BE3C-3FA25719A4CAQ30401304-4AF54E61-D700-4D8D-9B87-C46574B4B81CQ30402018-998CFC54-9F12-4116-83CF-F987D12D3063Q30408091-5B21E0F2-017B-4CA3-816F-3068B35564C5Q30411859-F81E0965-53C2-4C59-84A6-9256B3A5490CQ30416922-71DE5420-B3FC-4F7B-A842-E1728FEC9E80Q30417273-4A37D28C-60B1-4C25-8F8C-D6277C672394Q30420397-3B8359BE-BD3D-4BB5-A67E-C762F9F5A330Q30420479-E014BEE6-A8BA-4848-9BF9-AF6D4BBA14EDQ30426236-622E21CA-1394-4D7C-A91A-E09E22CFC392Q30913948-9EE059DB-090A-429C-BBEB-1E8DE33EED3AQ34067461-67D01699-746B-45D0-B5AC-94DE029D56E6Q34497705-25131835-714A-4FB2-B57C-FADF2ADD994EQ35094040-B01A2EEF-EA69-4266-84E4-8ED29E5591B2Q35960780-F7A73249-6DB8-40D3-93A3-B6251569D8CDQ36621905-3FDA46B5-31C1-4AF4-91DB-F108765CA8A1Q37157152-8C1D2258-87DB-4E9C-B8F8-38B601F496A0
P2860
An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
An adjuvanted, low-dose, pande ...... e responses in healthy adults.
@ast
An adjuvanted, low-dose, pande ...... e responses in healthy adults.
@en
type
label
An adjuvanted, low-dose, pande ...... e responses in healthy adults.
@ast
An adjuvanted, low-dose, pande ...... e responses in healthy adults.
@en
prefLabel
An adjuvanted, low-dose, pande ...... e responses in healthy adults.
@ast
An adjuvanted, low-dose, pande ...... e responses in healthy adults.
@en
P2093
P356
P1476
An adjuvanted, low-dose, pande ...... e responses in healthy adults.
@en
P2093
Anne-Diane Kervyn
Corinne Vandermeulen
Inca Kusters
Isabel Leroux-Roels
Karel Hoppenbrouwers
Karin Levie
Sheron Forgus
Sylvie Pichon
P304
P356
10.1086/590913
P407
P577
2008-09-01T00:00:00Z